Navigation Links
FDA Approves Redesigned Labels for Some Merck Drugs
Date:6/10/2011

ref="http://www.fda.gov/Safety/MedWatch/default.htm">http://www.fda.gov/Safety/MedWatch/default.htm

How to Report a Medication Error

http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Morgan Liscinsky, 301-796-0379, morgan.liscinsky@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... M. Bergman, Chairman and Chief Executive Officer of ... the largest provider of health care products and ... impact of a world without effective antibiotics before ... leaders of society at the World Economic Forum,s ...
... 2012  Vision-Sciences, Inc. (NASDAQ:  VSCI), a leading provider ... disposable EndoSheath® technology, today announced its participation at ... TIME: 2:30 PM EST ... "register/ watch event now" button. This ...
Cached Medicine Technology:Henry Schein's Chairman and CEO Addresses the World Economic Forum 2Henry Schein's Chairman and CEO Addresses the World Economic Forum 3Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd 2
(Date:5/21/2013)... Atlanta, GA (PRWEB) May 21, 2013 ... Care, ScripNet and Procura Management, today announced that ... Award at Catamaran’s client advisory meeting. Conferred ... has partnered with Catamaran to create cutting edge ... This year, Healthcare Solutions was recognized for its ...
(Date:5/21/2013)... May 21, 2013 Two-thirds of patients ... cell lung cancer reported that they engage in at ... use, according to new findings from the National ... Kantar Health . The research will be presented today ... Society for Pharmacoeconomics and Outcomes Research) in New Orleans. ...
(Date:5/21/2013)... 2013 A plastic surgery Internet ... plastic surgery SEO services following an Internet survey. ... name the “Best Plastic Surgery SEO Services”. , ... was predictable. Well-known in the plastic surgery Internet ... than any other selection based on superior client ...
(Date:5/21/2013)... May 21, 2013 It’s nearly summer and ... camp or starting practice for summer or fall sports. ... or sporting activities can begin. , To help parents ... for youth sports or camp physicals at just ... will review a child’s medical history, perform a physical exam ...
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives and ... Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate Casa ... facility serves meals and provides a social outlet for 45 ... Platinum Vice President, Mike Muench, says that the idea for ... “Platinum got its start selling long-term care insurance ,” ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Receives Innovation Award From Catamaran 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3
... release is available in French . ... could be closer to reality, thanks to a discovery ... Hospital Research Centre. According to a study published in ... have become the first to clone, produce and purify ...
... patients with weakened immune systems. So it would seem ... prime breeding ground for infections because of the constantly ... whom could be exposed to bacteria and viruses at ... among the most common causes of illness and death ...
... Technology from Xiotech Selected by National Provider ... Minn., March 17 Xiotech Corporation today ... Emprise(TM) 7000 storage system, powered by Intelligent ... virtualization initiative. Milliman Care Guidelines will use ...
... 17 Siemens Energy & Automation, Inc. ... Mass., has selected Simatic(R) PCS 7 Lab ... manage pre- and post-clinical experimental data.(Logo: ... therapeutics based upon their novel polymeric nanoparticle ...
... (Hologic or the Company) (Nasdaq: HOLX ), ... medical imaging systems and surgical products dedicated to serving ... release its second quarter fiscal 2009 operating results on ... with the release, management will host a conference call ...
... Psychiatry , published by Elsevier, is very pleased to ... devoted to fundamental new insights into epigenetics, a field ... produce long-lasting or even heritable changes in gene function ... epigenetics in psychiatry promises several key advances, as noted ...
Cached Medicine News:Health News:Researchers clone key sperm-binding proteins 2Health News:Patient Infection Rates Controlled by Unique Program at Outpatient Cancer Clinic 2Health News:Patient Infection Rates Controlled by Unique Program at Outpatient Cancer Clinic 3Health News:Patient Infection Rates Controlled by Unique Program at Outpatient Cancer Clinic 4Health News:Emprise 7000 Storage System, with ICON Manager and Virtual View Integration, Helps Milliman Care Guidelines Simplify Storage Management 2Health News:Emprise 7000 Storage System, with ICON Manager and Virtual View Integration, Helps Milliman Care Guidelines Simplify Storage Management 3Health News:Emprise 7000 Storage System, with ICON Manager and Virtual View Integration, Helps Milliman Care Guidelines Simplify Storage Management 4Health News:BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S. 2Health News:BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S. 3Health News:Hologic to Release Second Quarter Fiscal 2009 Operating Results on Monday, May 4, 2009 2Health News:Understanding mental illness through gene-environment interactions 2
... long-life Active RFID tags using the wireless ... mobile assets or people, AeroScout enables the ... many different assets for the purpose of ... T2 Tag can be programmed via a ...
... Labels have a direct thermal print ... Tag-it™ HF-I transponder. When processed through ... and other graphics may be printed ... is programmed to the RFID transponder. ...
The PDC Smart® Key Fob can be programmed on demand using a 13.56 MHz RFID reader/writer and is ideal for long-term use applications such as electronic access control or loyalty programs....
... SURGICHIP™ is a patent pending solution ... embedded in a smart label to ... prevent wrong-patient, wrong-site, wrong-procedure surgery. This ... by an orthopedic surgeon with the ...
Medicine Products: